Biohaven price target raised to $76 from $66 at Piper Sandler

Piper Sandler analyst Christopher Raymond raised the firm’s price target on Biohaven to $76 from $66 and keeps an Overweight rating on the shares. The company’s spinocerebellar ataxia data for troriluzole were “surprisingly robust and overwhelmingly positive outcome,” the analyst tells investors in a research note. The firm now models this opportunity with launch next year and U.S. revenue going to $250M by 2030.